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ABSTRACT
The aim of the present study was to examine the relationship between tumour cell 
expression of total and phosphorylated STAT1 (ph-STAT1) and STAT3 (ph-STAT-3), 
components of tumour microenvironment and survival in patients with invasive ductal 
breast cancer.
Immunohistochemical analysis of total and ph-STAT1, and STAT3 were performed 
on tissue microarray of 384 breast cancer specimens. Tumour cell expression of STAT1 
and STAT3 at both cytoplasmic and nuclear locations were combined and identified as 
STAT1/STAT3 tumour cell expression. These results were related to cancer specific 
survival (CSS) and phenotypic features of the tumour and the host.
High ph-STAT1 and ph-STAT3 tumour cell expression were associated with 
increased ER (both P≤0.001) and PR (both P <0.05), reduced tumour grade (P=0.015 
and P<0.001 respectively) and necrosis (both P=0.001). Ph-STAT1 was associated 
with increased general inflammatory infiltrate (P=0.007) and ph-STAT3 was 
associated with lower CD4+ infiltration (P=0.024). In multivariate survival analysis, 
only high ph-STAT3 tumour cell expression was a predictor of improved CSS (P=0.010) 
independent of other tumour and host-based factors.
STAT1 and STAT3 tumour cell expression appeared to be an important 
determinant of favourable outcome in patients with invasive ductal breast cancer. The 
present results suggest that STAT1 and STAT3 may affect disease outcome through 
direct impact on tumour cells, counteracting aggressive tumour features, as well as 
interaction with the surrounding microenvironment.
INTRODUCTION
Breast cancer is the most frequent malignancy in 
women, accounting for 25% of all female cancers, with 
more than a million women diagnosed annually. It is also 
the leading cause of cancer death in women with >500,000 
deaths in 2012 worldwide [1]. Therefore, it is clear that 
there is a need to identify characteristics applicable to both 
the tumour and the host to not only guide prognosis, but 
also identify potential therapies.
Components of tumour microenvironment, 
including tumour stroma and tumour inflammatory cell 
infiltrates are now recognised to play a key role in cancer 
progression and survival, and represent interactions 
between the tumour and the host [2, 3]. However, the 
underlying mechanism of the interaction between the 
different components of tumour microenvironment is not 
fully understood. Cross-talk between signaling pathways 
determine how a cell integrates the environmental signals 
received, ultimately translating them in transcriptional 
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regulation of specific sets of genes [4]. Signal transducers 
and activators of transcription family (STATs) have been 
recognized to act downstream of cytokine and growth 
factor receptors [4, 5], and may therefore play a central 
role in determining the phenotypic characteristics of the 
tumour.
The IL-6/Janus-activated kinase can trigger tyrosine 
phosphorylation of both STAT1 and STAT3 through 
homo- or hetero-dimerization of the signal transduction 
subunit gp130 [6]. STATs detect a variety of signals at 
the cell membrane and transduce them to the nucleus 
directly affecting gene regulation of cell growth, survival, 
differentiation, and motility. STAT1 is a central mediator 
of both type I and type II interferon (IFN) [7, 8], however 
both IFNs can also activate STAT3 (6).
STAT1 and STAT3 have a complex interaction 
with both tumour cells and the tumour microenvironment 
including immune infiltrates such that STAT1 and STAT3 
are thought to play opposite roles in tumorigenesis, 
regulating distinct gene signatures [9]. STAT1 has been 
considered as a growth suppressor based on its role as a 
pro-apoptotic and anti-proliferative molecule [4, 5]. STAT3 
is well established as a key factor in mammary epithelial 
cell growth and differentiation behaving as an oncogene 
[10] and also, is essential in mammary gland epithelial cell 
apoptosis and involution [11, 12]. Furthermore, studies in 
STAT-deficient cells/animals have revealed the existence 
of reciprocal STAT1 to STAT3 regulatory mechanisms that 
represent cross-regulation between the two molecules [9] 
such that STAT3 gene inactivation results in increased and 
prolonged phosphorylation of STAT1 in response to gp130 
cytokines [6, 9].
Despite the fact that several experimental studies 
suggest that STAT1 and STAT3 play a critical role in 
breast cancer tumorigenesis, the prognostic value of 
these proteins in patients with breast cancer remains 
unclear. Five studies have examined the prognostic value 
of STAT1 in breast cancer, using either total STAT1 or 
phosphorylated STAT1 (ph-STAT1) (Table 1). An initial 
analysis by Widschwendter et al using Western blotting 
and DNA binding technique, reported an independent 
association between high ph-STAT1 and improved overall 
and cancer specific survival (CSS) [13]. In contrast, 
immunohistochemistry (IHC) of ph-STAT1, found that 
ph-STAT1 in premenopausal women was associated with 
poor overall survival, but not in postmenopausal women. 
However, co-expression of ph-STAT1 with ER or PR was 
associated with longer CSS in postmenopausal women 
[14]. Studies measuring total STAT1 have also reported 
conflicting results. High total STAT1 was not associated 
with outcome in two studies [15, 16] and was a significant 
predictor of worse survival in one study [17] (Table 1).
Ten studies have examined the prognostic value 
of STAT3 in breast cancer, using either total STAT3 or 
phosphorylated STAT3 (ph-STAT3) (Table 1). High 
total STAT3 was significantly associated with improved 
outcome in three studies [16, 18, 19], and with poor 
outcome in one study [20]. Ph-STAT3 expression was 
not associated with breast cancer survival in two studies 
[13, 21], and was associated with improved survival 
in large cohort of patients [22], patients with lymph 
node positive tumours [23], and patients treated with 
adjuvant chemotherapy [24]. In contrast, ph-STAT3 was 
a significant predictor of worse survival in one study [17] 
(Table 1). Therefore, given that clinical trials evaluating 
Il-6/JAK/ STAT inhibitors in breast cancer patients are 
under way [25], it would be important to determine the 
role of STAT1 and STAT3 in this disease.
Also, commensurate with their role in regulating 
cytokine-dependent inflammation and immunity, the 
relationship between STAT1 and STAT3 and components 
of tumour microenvironment is unclear. Therefore, the 
aim of the present study was to examine the relationship 
between total and phosphorylated STAT1 and STAT3 
tumour cell expression, components of the tumour 
microenvironment and survival in a mature cohort of 
patients with invasive ductal breast cancer.
RESULTS
Total and ph-STAT1 and STAT3 expression 
in tumour cells were quantified using the weighted 
histoscore, taking the staining intensity and percentage 
into account (material and methods). The IHC staining 
of total and ph-STAT1 and STAT3 was homogenous in 
both the cytoplasm and nuclei of tumour cells, which is 
consistent with previous reports [22]. The staining was 
also observed in the surrounding stromal cells (fibroblasts 
and infiltrating inflammatory cells) with variable degrees 
of positivity. Figure 1 displays images representative of 
STAT1 and STAT3 IHC staining.
The histoscore of total STAT1 expression ranged 
from 0-200 within the cytoplasm and from 0-220 within 
the nucleus, with cytoplasmic and nuclear expression in 
270 patients (70%) and 268 patients (70%) respectively. 
The histoscore for ph-STAT1 expression ranged from 
0-190 within the cytoplasm and from 0-225 within the 
nucleus, with cytoplasmic and nuclear expression in 350 
patients (91%) and 374 patients (97%) respectively. Total 
STAT1 cytoplasmic expression was not correlated with 
ph-STAT1 nuclear expression (P=0.421). Expression of 
total STAT1 and ph-STAT1 within the nucleus correlated 
strongly with their expression within the cytoplasm (all 
P<0.001).
The histoscore of total STAT3 expression ranged 
from 0-280 within the cytoplasm and from 0-293 within 
the nucleus, with cytoplasmic and nuclear expression 
in 375 patients (98%). The histoscore of ph-STAT3 
expression ranged from 0-150 within the cytoplasm 
and from 0-250 within the nucleus, with cytoplasmic 
and nuclear expression in 359 patients (93%) and 376 
patients (98%) respectively. Total STAT3 tumour cell 
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expression correlated strongly with ph-STAT3 tumour cell 
expression (P<0.001). Expression of total STAT3 and ph-
STAT3 within the nucleus correlated strongly with their 
expression within the cytoplasm (all P<0.001).
The clinical and pathological characteristics of 
patients with invasive ductal breast cancer are shown 
in Table 2. The majority of patients aged 50 years or 
older (70%), had a tumour size ≤ 2 cm (61%), grade 
III carcinoma (43%) with negative axillary lymph node 
involvement (54%). The majority had ER positive tumours 
(68%), PR positive tumours (60%) and Her-2 negative 
tumours (79%), with high grade tumour necrosis (53%). 
241 (63%) patients had mastectomy with radiotherapy, 
194 (51%) patients received only hormonal therapy, 90 
(23%) received only chemotherapy, and 70 (18%) received 
both. 174 (45%) of patients had Luminal A tumours, 92 
(24%) had Luminal B tumours, 30 (8%) had Her-2 positive 
tumours and 68 (18%) had Triple negative tumours.
The relationship between ph-STAT1 and ph-
STAT3 tumour cell expression and clinicopathological 
characteristics was shown in Table 3. Ph-STAT1 tumour 
cell expression was not associated with patient age, 
tumour size, Her-2 status, or the presence of lymphatic 
(LVI) and blood (BVI) vessel invasion. High ph-STAT1 
Table 1: Studies on the prognostic significance of STAT1 and STAT3 in breast cancer
References Patients Sample size
Follow-
up
Protein 
examined Association with outcome
STAT1 studies
Widschwendter et al., 2002 N/S 53 6.8 ph-STAT1 associated with improved overall and 
CSS (multivariate analysis)
Sheen Chen et al., 2007 N/S 102 5.8 total STAT1 no association with overall survival
Charpin et al., 2009 N/S 924 6.5 total STAT1 associated with reduced CSS
Magkou et al., 2012
Premenopausal/
postmenopausal 165 7.5 ph-STAT1
in premenopausal women: associated 
with poor OS (univariate analysis)
in postmenopausal women: co-
expression with ER/or PR was 
associated with improved CSS 
(univariate analysis)
Huang et al., 2014 N/S 546 15 total STAT1 no significant association with CSS
STAT3 studies
Widschwendter et al., 2002 N/S 53 6.8 ph-STAT3 no association with survival
Dolled-Filhart et al., 2003 LN -ve 255 5 & 20 total STAT3 associated with improved OS
Yamashita et al., 2006 N/S 506 7.5 ph-STAT3 no association with OS and CSS
Sheen-Chen et al., 2008 N/S 102 5 total STAT3 associated with reduced OS
Charpin et al., 2009 N/S 924 6.5 ph-STAT3 associated with reduced CSS
Sato et al., 2011
all, LN-ve/ 
LN+ve, low & 
high grade
721 >10 total STAT3
associated with improved OS in 
patients with low grade tumours 
(univariate analysis)
Sonnenblick et al., 2012 LN +ve 125 5 & 10 ph-STAT3 associated with improved OS
Sonnenblick et al., 2013 N/S 375 10 ph-STAT3
associated with improved OS in 
patients treated with adjuvant 
chemotherapy
Huang et al., 2014 N/S 546 15 total STAT3 associated with improved CSS 
(univariate analysis)
Aleskandarany et al., 2016 N/S 1270 N/A Ph-STAT3
associated with improved CSS 
(multivariate analysis)
N/S: not specified invasive breast cancer, LN: lymph node, ph-STAT1 tyrosine phosphorylated STAT1, ph-STAT3: tyrosine 
phosphorylated STAT3, CSS: cancer specific survival. OS: overall survival, Follow-up in years. N/A: not available.
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tumour cell expression was positively associated with ER 
status (P=0.001), PR status (P=0.048), and negatively with 
increased tumour grade (P=0.015). Similarly, ph-STAT3 
tumour cell expression was not associated with patient 
age, tumour size and Her-2 status, though borderline 
significant associations with reduced LVI (P=0.055) and 
BVI (P=0.052) were observed. High ph-STAT3 tumour 
cell expression was positively associated with ER status 
(P<0.001), PR status (P=0.015) and negatively with 
increased tumour grade (P<0.001).
Within the tumour microenvironment, high ph-
STAT1 tumour cell expression was not associated with 
tumour stroma percentage (TSP) and tumour budding. 
High ph-STAT1 tumour cell expression was negatively 
associated with tumour necrosis (P=0.001), and was 
positively associated with the generalised inflammatory 
infiltrate as measured using Klintrup–Mäkinen (K-M) 
grade (P=0.007). Similarly, high ph-STAT3 tumour cell 
expression was not associated with TSP and tumour 
budding. High ph-STAT3 tumour cell expression was 
negatively associated with tumour necrosis (P=0.001) and 
cellular inflammatory infiltrate as measured using CD4+ 
helper T-lymphocytes (P=0.024). High ph-STAT1 and 
ph-STAT3 tumour cell expression were also significantly 
associated with reduced tumour recurrence (P=0.003 and 
P=0.001 respectively).
The median follow-up of survivors was 148 
months, with 82 cancer-associated deaths and 74 non-
cancer deaths. The relationship between total and ph-
STAT1 tumour cell expression and CSS using Kaplan-
Meier log rank test was examined (Figure 2). The total 
STAT1 tumour cell expression was not associated with 
CSS (P=0.435) (Figure 2A). High ph-STAT1 tumour cell 
expression was associated with improved CSS compared 
to low tumour cell expression (P=0.002) (Figure 2B). The 
mean survival of patients with low ph-STAT1 tumour cell 
expression was 140 months (95% CI 129-151 months) and 
10-year survival rate was 68%, whereas the mean survival 
of patients with high expression was 160 months (95% CI 
152-169 months) and 10-year survival rate was 84%.
The relationship between total and ph-STAT3 
tumour cell expression and CSS using Kaplan-Meier log 
rank test was subsequently examined (Figure 2). Total 
STAT3 tumour cell expression was associated with CSS 
(P<0.001) (Figure 2C). High ph-STAT3 tumour cell 
expression was associated with improved CSS compared 
to patients with low tumour cell expression (P<0.001) 
(Figure 2D). The mean survival of patients with low 
expression was 139 months (95% CI 129-149 months) 
and 10-year survival was 62%, whereas the mean survival 
of patients with high expression was 170 months (95% CI 
163-176 months) and 10-year survival was 80%.
The relationship between ph-STAT1 and ph-STAT3 
tumour cell expression, clinicopathological characteristics, 
and CSS is presented in Table 4. In univariate analysis, 
both high ph-STAT1 (P=0.002) and ph-STAT3 (P<0.001) 
tumour cell expression were associated with improved 
CSS. In multivariate analysis, high ph-STAT1 tumour 
cell expression was not independently associated with 
CSS (P=0.193). In contrast, high ph-STAT3 tumour cell 
Figure 1: Sections of invasive ductal beast carcinomas showing IHC expression levels of ph-STAT1 (first row) and ph-
STAT3 (second row). No appreciable expression was detected in the negative controls of ph-STAT1 A. and ph-STAT3 B. C-H. show the 
staining intensity of the STAT1 and STAT3 expression as low (C and D), moderate (E and F), and strong (G and H). Original magnification, 
20×. Scale bars = 100 μm (A-F), 10 μm (G and H).
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expression was independently associated with improved 
CSS (HR 0.64, 95% CI 0.64-0.90, P=0.010) independent 
of other variables, including nodal status, tumour necrosis, 
LVI, BVI, CD8+ T-lymphocyte infiltrate, CD138+ plasma 
cell infiltrate, and tumour budding (Table 4).
Due to the strong association observed between 
both ph-STAT1 and ph-STAT3 and tumour necrosis, the 
relationship between ph-STAT1 and ph-STAT3 tumour 
cell expression with CSS in patients with high tumour 
necrosis was subsequently examined (Table 5). In 
univariate analysis, high ph-STAT3 but not ph-STAT1 
tumour cell expression was significantly associated with 
improved CSS. In multivariate analysis, high ph-STAT3 
tumour cell expression was significantly associated with 
improved CSS (HR 0.69, 95% CI 0.51-0.95, P=0.030) 
independent of LVI, BVI, CD68+ macrophage infiltrate, 
CD8+ T-lymphocyte infiltrate, tumour budding and 
locoregional treatment (Table 5).
The relationship between ph-STAT1 and ph-STAT3 
tumour cell expression and CSS using Kaplan-Meier log 
rank test, with relevance to different molecular subtypes, 
was examined (Figure 3 and 4). High ph-STAT1 was 
significantly associated with improved CSS in luminal 
A (n=174) tumours (P=0.007). High ph-STAT3 was 
significantly associated with improved CSS in luminal 
A (n=174) (P=0.005) and B (n=92) tumours (P=0.017). 
The small Her-2 positive subtype cohort (n=30) precluded 
meaningful analysis.
DISCUSSION
In the present study, increased tumour cell 
expression of both ph-STAT1 and ph-STAT3 was 
associated with improved survival and the phenotypic 
characteristics of the tumour, in particular the low tumour 
grade and lack of tumour necrosis. Therefore, activation of 
Table 2: The clinicopathological characteristics of patients with invasive ductal
Clinicopathological characteristics Patients, n (%)
Age (≤50/ >50 years) 116(30%)/268(70%)
Size (≤20/ 21-50/ >50 mm) 233(61%)/142(37%)/9(2%)
Grade (I / II / III) 71(19%)/147(38%)/166(43%)
Involved lymph node (-ve/+ve) 209(54%)/172(45%)*
ER status (no/yes) 116(30%)/268(68%)
PR status (no/yes) 152(40%)/230(60%)*
Her-2 status (no/ yes) 305(79%)/70(18%)*
Lymphaic vessel invasion (no/yes) 254(66%)/130(34%)
Blood vessel invasion (no/yes) 340(88%)/44(12%)
Tumour necrosis (low/high) 183(48%)/201(52%)
Klintrup–Mäkinen grade (low/high) 272(71%)/112(29%)
CD68+ (low/moderate/high) 116(30%)/129(34%)/124(32%)*
CD4+ (low/moderate/high) 160(42%)/75(20%)/136(35%)*
CD8+ (low/moderate/high) 124(32%)/119(31%)/128(33%)*
CD138+(low/moderate/high) 203(53%)/45(12%)/122(32%)*
Tumour stroma percentage (low/high) 264(69%)/120(31%)
Tumour budding (low/high) 250(65%)/134(35%)
Locoregional treatment (lumpectomy + 
radiotherapy/mastectomy +radiotherapy)
143(37%)/241(63%)
Systemic treatment (hormonal/hormonal+ 
chemotherapy/chemotherapy/ none)
194(51%)/70(18%)/90(23)/24(6%)*
Recurrence status (no/yes) 285(74%)/95(25%)*
Alive/cancer death/non cancer death 228(59%)/82(22%)/74(19%)
*Number of patients when incomplete data available.
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tumour STATs may be an important mechanism by which 
the tumour cells mitigate the development of an aggressive 
phenotype in patients with invasive ductal breast cancer.
To our knowledge no previous study have conducted 
a comprehensive analysis of total and phosphorylated 
STAT1 and STAT3 expression in patients with ductal 
breast cancer. Ph-STAT1 and ph-STAT3 were strongly 
associated with each other independent of cellular location. 
In multivariate analysis, ph-STAT1 was independently 
associated with prolonged CSS, however when ph-STAT3 
was also included in the model only ph-STAT3 remained 
independently associated with CSS. These results suggest 
that ph-STAT3 is the dominant STAT protein associated 
with improved survival in patients with invasive ductal 
breast cancer.
The observation that STAT1 is associated with 
improved survival may be explained by its role in 
promoting apoptosis and inhibition of proliferation [26]. 
STAT1 induces apoptosis by up-regulation of caspases 
2 and 3 expression [27, 28] and recently Magou and 
colleagues have reported a positive association between 
ph-STAT1 and caspase 3 expression in primary breast 
cancer tissues [14]. Furthermore, STAT1 has been reported 
to inhibit the development of mammary tumours in 
experimental models [29, 30]. In certain contexts STAT3 
also behaves as a tumour-suppressor protein targeting 
Table 3: The relationship between ph-STAT1 and ph-STAT3 tumour cell expression and clinicopathological 
characteristics (n=384)
Ph-STAT1 tumour cell expression Ph-STAT3 tumour cell expression
low moderate high P value low moderate high
P valuen=127,  
33%
n=136,  
35%
n=121, 
32%
n=154, 
40%
n=121,  
32%
n=109, 
28%
Age (≤50/ >50 years) 35/92 38/98 43/78 0.175 46/108 40/81 30/79 0.744
Size (≤20/21-50/>50 mm) 73/48/6 88/47/1 72/47/2 0.444 91/58/5 73/46/2 69/38/2 0.402
Grade (I / II / III) 17/43/67 29/53/54 25/51/45 0.015 14/60/80 25/47/49 32/40/37 <0.001
Lymph node status (-ve/+ve) 63/62 78/57 68/53 0.357 76/76 66/55 67/41 0.057
ER status (no/yes) 50/77 41/95 25/96 0.001 66/88 32/89 18/91 <0.001
PR status (no/yes) 57/70 56/79 39/81 0.048 70/83 49/72 33/75 0.015
Her-2 status (no/ yes) 99/26 102/29 104/15 0.105 120/31 94/25 91/14 0.173
Tumour necrosis (low/high) 45/82 69/67 69/52 0.001 60/94 57/64 66/43 0.001
Lymphatic vessel invasion  
(no/yes)
85/42 89/47 80/41 0.890 96/58 77/44 81/28 0.052
Blood vessel invasion (no/yes) 109/18 123/13 108/13 0.390 133/21 104/17 103/6 0.055
Klintrup–Mäkinen grade  
(low/high)
97/30 98/38 77/44 0.007 108/46 81/40 83/26 0.347
CD68+ (low/moderate/high) 40/47/33 40/39/54 36/43/37 0.514 49/53/45 42/33/42 25/43/37 0.183
CD4+ (low/moderate/high) 47/30/44 55/28/51 58/17/41 0.297 57/30/61 51/18/48 52/27/27 0.024
CD8+ (low/moderate/high) 46/38/37 39/51/44 39/30/47 0.179 52/43/53 36/39/42 36/37/33 0.785
CD138+(low/moderate/high) 65/14/42 74/14/45 64/17/35 0.613 90/15/42 61/12/44 52/18/36 0.109
Tumour strtoma percentage  
(low/high)
83/44 93/43 88/33 0.212 99/55 91/30 74/35 0.426
Tumour budding (low/high) 88/39 79/57 83/38 0.884 96/58 76/45 78/31 0.140
Locoregional treatment 
(lumpectomy+radiotherapy/
mastectomy +radiotherapy)
47/80 52/84 44/77 0.920 55/99 43/78 45/64 0.385
Systemic treatment (hormonal/
hormonal+ chemotherapy/
chemotherapy/ none)
58/23/37/8 70/27/28/10 66/20/25/6 0.102 72/26/48/7 57/24/30/7 65/20/12/10 0.060
Recurrence status (no/yes) 86/40 99/37 100/18 0.003 105/49 88/32 92/14 0.001
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genes involved in apoptosis and induction of growth 
arrest [10, 31]. In particular, STAT3 is activated during the 
apoptotic involution of mammary gland [11, 12, 32] and 
the suppression of brain tumours [33]. Indeed, consistent 
with such a scheme, Sato and colleagues, a large dataset 
of more than 700 patients, reported that expression of 
ph-STAT3 was reduced in the progression from normal 
breast epithelia to invasive and metastatic breast cancer 
[19]. Furthermore, STAT3 has been shown to up-regulate 
tissue inhibitor of metalloproteinase-1 expression, which 
is recognised to reduce the invasiveness of breast cancer 
cells [34].
The results of the present study are consistent 
with the majority of previous reports where 6/10 studies 
reported that ph-STAT3 was associated with improved 
outcome (Table 1). Studies reporting no or poor prognosis 
in breast cancer were mainly performed in small 
cohorts, cohorts with limited follow-up, or had potential 
confounding factors. The present study was carried out in 
a cohort of ductal tumours with mature follow-up.
It is plausible that STAT1 and STAT3 have 
prognostic value in different tumour types, different 
molecular subtypes or in different aspects of the tumour 
microenvironment. In the present study, the prognostic 
role of ph-STAT1 and ph-STAT3 tumour cell expression 
in different molecular subtypes was examined. Ph-STAT1 
and ph-STAT3 were significant predictors of prolonged 
CSS in luminal subtypes. Also, both ph-STAT1 and ph-
STAT3 were directly associated with ER positive status. 
This may indicate that the role of STATs in breast cancer 
may be driven by endocrine hormones and support 
the cross-talk with ER [35, 36]. Previous reports have 
shown that patients with low proliferating luminal A 
tumours have higher ph-STAT3 expression compared to 
those with the luminal B tumours [37]. Furthermore, in 
ER negative, Her-2 positive tumours, no response was 
observed to trastuzumab in patients with STAT3 activation 
[38] and that JAK2 drives a JAK1/STAT3-independent 
signaling program in triple negative breast cancer [39], 
demonstrated that there are different activators and targets 
for STAT3 in different subgroups of breast cancer.
The present study reported an association between 
ph-STAT1, ph-STAT3 and the inflammatory cell infiltrate. 
High ph-STAT1 tumour cell expression was associated 
with up-regulation of local inflammatory infiltrate 
as evidenced by increased generalised inflammatory 
Figure 2: Kaplan-Meier survival curves (Log rank) of cancer specific survival. A. Total STAT1 tumour cell expression and B. 
Ph-STAT1 tumour cell expression. C. Total STAT3 tumour cell expression and D. Ph-STAT3 tumour cell expression.
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cell infiltrate. In contrast, high ph-STAT3 tumour cell 
expression was associated with down-regulation of the 
local inflammatory infiltrate as evidenced by decrease in 
the CD4+ T-lymphocytes. It was of interest that STAT1 
and STAT3 were expressed in both the stroma fibroblasts 
and cells of the inflammatory infiltrate (Figure 1). Taken 
together, the results of the present study would suggest an 
important role for STAT1 and STAT3 in regulating anti-
tumour immunity in the breast tumour microenvironment 
[40]. Such findings may be important in therapies to 
counteract immune dysfunction and improve cancer 
immunotherapy [9].
The present study reports for the first time a 
negative association between ph-STAT1 and ph-STAT3 
expression and tumour necrosis. Moreover, that elevated 
ph-STAT3 expression was significantly associated with 
better survival, suggesting a protective role of STAT3 
against tumour necrosis. The basis of such an observation 
is not clear, however it is of interest that IFNγ-induced 
STAT1 activation has been previously shown to negatively 
regulate hypoxia-inducible factor-1 (HIF-1) α-dependent 
transcription in human glioblastoma cells lines [41]. HIF-
1 is a master regulator of the transcriptional response to 
hypoxia [42]. Indeed, constitutively active STAT3 acts as 
a master regulator of cell metabolism, inducing aerobic 
glycolysis via HIF-1 α transcriptional induction [43] as it 
is part of the complex signaling network that shapes the 
metabolic phenotype of tumour cells. Tumour hypoxia 
has been shown to be associated with a more clinically 
aggressive phenotype, resistance to therapy, angiogenesis 
Table 4: The relationship between clinicopathological characteristics, ph-STAT1 and ph-STAT3 tumour cell 
expression and cancer specific survival in patients with invasive ductal breast cancer (n=384)
Univariate analysis Multivariate analysis
HR (95% CI) P-value HR (95% CI) P-value
Age (≤50/ >50 years) 1.14(0.70-1.85) 0.604
Size (≤20/ 21-50/ >50 mm) 2.21(1.52-3.23) <0.001 0.475
Grade (I / II / III) 1.89(1.37-2.63) <0.001 0.254
Involved lymph node (-ve/+ve) 3.85(2.37-6.24) <0.001 1.90(1.10-3.29) 0.021
ER status (no/yes) 0.54(0.35-0.84) 0.006 0.141
PR status (no/yes) 0.58(0.38-0.90) 0.015 0.181
Her-2 status (no/ yes) 2.05(1.26-3.32) 0.004 0.272
Tumour necrosis (low/high) 5.87(3.26-10.67) <0.001 4.42(2.31-8.45) <0.001
Lymphatic vessel invasion (no/yes) 4.08(2.61-6.37) <0.001 1.94(1.13-3.31) 0.015
Blood vessel invasion (no/yes) 3.28(1.98-5.43) <0.001 1.79(1.02-3.14) 0.044
Klintrup–Mäkinen grade (low/high) 1.47(0.93-2.23) 0.099 0.526
CD68+ (low/moderate/high) 0.79(0.59-1.02) 0.069 0.101
CD4+ (low/moderate/high) 0.99(0.78-1.26) 0.982
CD8+ (low/moderate/high) 0.62(0.47-0.82) <0.001 0.58(0.42-0.80) 0.003
CD138+(low/moderate/high) 1.34(1.06-1.69) 0.014 1.65(1.25-2.18) <0.001
Tumour stroma percentage (low/high) 2.17(1.40-3.35) <0.001 0.096
Tumour budding (low/high) 2.46(1.59-3.78) <0.001 1.88(1.17-3.03) 0.009
Ph-STAT1 tumour cell expression (low/
moderate/high)
0.65(0.49-0.86) 0.002 0.193
Ph–STAT3 tumour cell expression (low/
moderate/high)
0.54(0.40-0.74) <0.001 0.64(0.64-0.90) 0.010
Locoregional treatment (lumpectomy 
+radiotherapy/mastectomy+radiotherapy)
2.62(1.55-4.42) 0.001 0.054
systemic treatment (hormonal/hormonal 
+chemotherapy/chemotherapy/none)
1.26(1.02-1.55) 0.020 0.408
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and metastasis [44]. Therefore, further understanding 
of the molecular mechanism by which STAT1 down-
regulates hypoxia-induced transcription may also lead to 
the development of a better therapeutic measure for cancer 
treatment.
Taken together, the results of the present study 
would suggest that both STAT1 and STAT3 act as tumour-
suppressor proteins in patients with ductal breast cancer. 
STAT1 has long been implicated in growth suppression 
[26, 45] as loss of STAT1 function results in early 
development of breast tumours [29, 30]. Unlike other 
STAT members, the loss of STAT3 function results in 
early embryonic lethality STAT3 [46] and the suppression 
of tumour cell proliferation [47-49], suggesting its crucial 
role as an oncogenic factor. The mechanisms underlying 
STAT3 signalling pathway’s diverse and sometimes 
opposing roles are still largely unknown. Nevertheless, 
it would suggest that the pleomorphic role of STAT3 
in breast cancer prognosis, as an oncogene or a tumour 
suppressor, may be a function of the setting or cellular 
context, in particular the tumour microenvironment and 
necrosis. It may also suggest that there are other signal 
transduction pathways involved in the effect elaborated 
by tumour STAT3 expression. Irrespective, these results 
would indicate that STATs are central to the signaling 
networks in ductal breast cancer and that STAT3, in 
particular, has cross-talk with members of other pathways, 
such as the transcription factors HIF, and the nuclear factor 
kappa B [50, 51].
In the present study, although high ph-STAT1 and 
ph-STAT3 were associated with improved outcome, the 
clinical utility of targeting these pathways remains to be 
Table 5: The relationship between clinicopathological characteristics, ph-STAT1 and ph-STAT3 tumour cell 
expression and cancer specific survival in patients with high grade necrosis (n=201)
Univariate analysis Multivariate analysis
HR (95% CI) P-value HR (95% CI) P-value
Age (≤50/ >50 years) 1.15(0.68-1.94) 0.604
Size (≤20/ 21-50/ >50 mm) 1.66(1.09-2.50) 0.016 0.330
Grade (I / II / III) 1.17(0.78-1.73) 0.452
Involved lymph node (-ve/+ve) 2.36(1.39-4.03) 0.002 0.156
ER status (no/yes) 0.77(0.48-1.24) 0.303
PR status (no/yes) 0.78(0.49-1.27) 0.326
Her-2 status (no/ yes) 1.19(0.71-2.02) 0.503
Lymphatic vessel invasion (no/yes) 3.28(1.98-5.44) <0.001 2.53(1.45-4.44) 0.001
Blood vessel invasion (no/yes) 2.78(1.62-4.77) <0.001 2.03(1.14-3.59) 0.015
CD68+ (low/moderate/high) 0.68(0.51-0.89) 0.007 0.65(0.46-0.91) 0.013
CD4+ (low/moderate/high) 0.78(0.59-1.02) 0.064 0.425
CD8+ (low/moderate/high) 0.51(0.38-0.69) <0.001 0.65(0.47-0.76) 0.012
CD138+(low/moderate/high) 1.18(0.92-1.52) 0.195
Tumour stroma percentage (low/high) 2.14(1.32-3.47) 0.002 0.197
Tumour budding (low/high) 2.51(1.56-4.04) <0.001 1.91(1.14-3.19) 0.014
Ph-STAT1 tumour cell expression (low/
moderate/high)
0.83(0.63-1.12) 0.230
Ph–STAT3 tumour cell expression (low/
moderate/high)
0.65(0.46-0.90) 0.011 0.69(0.51-0.95) 0.030
Locoregional treatment 
(lumpectomy+radiotherapy/ mastectomy 
+radiotherapy)
2.37(1.33-4.20) 0.003 2.03(1.19-3.74) 0.024
Systemic treatment (hormonal/hormonal+ 
chemotherapy/chemotherapy/ none)
1.11(0.86-1.43) 0.415
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established. However, it is of interest that clinical trials 
evaluating Il-6/JAK/ STAT inhibitors in breast cancer 
patients are under way [25].
Potential limitations of the present study were that 
a specific examination of STAT1 and STAT3 in stromal 
tissue and in inflammatory cells was not carried since 
Chan and colleagues have reported that STAT1 expression 
may vary between tumour cells and the associated stroma, 
and have reported a selective loss of STAT1 expression 
in breast cancer cells but not in the surrounding stromal 
cells during tumour progression. Thus the increase in 
STAT1 levels in the subset of breast cancer cases that 
exhibit low STAT1 expression in the neoplastic cells 
could be explained by selective upregulation of STAT1 
transcription in the stromal cells alone [30].
In conclusion, STAT1 and STAT3 tumour cell 
expression appears to be an important determinant of 
favourable outcome in patients with invasive ductal breast 
cancer. The present results suggest that STAT3 may affect 
disease outcome through the direct impact on tumour 
cells counteracting aggressive tumour features, as well as 
interaction with the surrounding microenvironment.
MATERIALS AND METHODS
Study materials
Patients presenting with invasive ductal breast 
cancer at Glasgow Royal Infirmary, Western Infirmary, 
and Stobhill Hospital, in the West of Scotland, between 
1995 and 1998, and who had formalin-fixed paraffin 
embedded tissue blocks of the primary tumour available 
for evaluation were studied (n = 384). The study was 
approved by the Research Ethics Committee of the West 
Figure 3: Kaplan-Meier survival curves (Log rank) of ph-STAT1 in different molecular subtypes. Only Luminal A (n=174, 
45%) shows significant association between high tumour cell expression of ph-STAT1 (n=121, 32%) and improved cancer specific survival.
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Glasgow University Hospitals NHS Trust (REC reference 
is 07/s0704/61) and was performed according to the 
REMARK guidelines [52].
Clinicopathological data included age, tumour 
size, tumour grade, lymph node status, and type of 
surgery and use of adjuvant treatment (chemotherapy, 
hormonal therapy and/or radiotherapy) were retrieved 
from the routine reports. Tumour grade was assigned 
according to Nottingham Grading System. The ER and 
PR status were assessed on tissue microarrays (TMA) 
using immunohistochemistry with Dako ER antibody and 
Leica PR antibody, and scored according to the American 
Society of Clinical Oncology and College of American 
Pathologists guidelines with a cut-off value of 1% positive 
tumour nuclei [53]. Her-2 status was assessed on TMA as 
previously described i.e. a score 3+ is regarded as positive; 
2+ is regarded as equivocal, leading to referral for Her-2 
FISH; and 0 and 1+ are regarded as negative [54]. The 
molecular subtypes were defined as follows: Luminal 
A: oestrogen (ER) and/or progesterone receptor (PR) 
positive, Her-2 negative, low proliferative index (≤15%); 
Luminal B: hormone receptor positive, Her-2 positive, 
high proliferative index (>15%); Her-2 subtype: Her-2 
positive and hormone receptor negative, any proliferative 
index; and Triple negative: Her-2 negative, hormone 
receptor negative, any proliferative index.
Lymph (LVI) and blood (BVI) vessel invasion were 
assessed, on 2.5 μm thick sections, using IHC staining 
with the lymphatic endothelial marker D2-40 (Covance, 
Monoclonal Antibody, SIG-3730, USA) diluted 1:100 
and vascular endothelial marker Factor VIII (Mouse 
Monoclonal Antibody, NCL-L-Vwf, Leica, Newcastle, 
UK) diluted 1:100 as previously described [55].
Full-section haematoxylin and eosin (H&E) slides 
were used to score general local inflammatory infiltrate 
according to Klintrup-Mäkinen (KM) grade [56] and 
Figure 4: Kaplan-Meier survival curves (Log rank) of ph-STAT3 in different molecular subtypes. Luminal A (n=174, 
45%) and luminal B (n=92, 24%) show significant association between high tumour cell expression of ph-STAT3 (n=109, 28%) and 
improved cancer specific survival. Manipulation is permitted.
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tumour necrosis as previously described [57]. Briefly, 
tumours were scored on four-point scores based on 
appearances at the tumour invasive margin. A score of 
0 signified that there were no inflammatory cells at the 
tumour’s invasive margin; score 1 indicated mild and 
patchy inflammatory cells; score 2 denoted a prominent 
band-like inflammatory reaction at the invasive margin; 
and score 3 revealed a florid cup-like inflammatory 
infiltrate at the invasive edge. The extent of necrosis was 
assessed at high power as absent (only single-cell death 
identifiable); mild (necrosis in <25% of fields); moderate 
(necrosis in 25-50% of fields) and extensive (confluent 
necrosis in >50% of fields) which then grouped into low 
and high grade.
Individual immune cells infiltrate was assessed using 
IHC staining on TMA sections for macrophages, helper 
and cytotoxic T-lymphocytes, and plasma cells using 
CD68, CD4, CD8 and CD138 antibodies respectively, as 
previously described [58].
Full-section H&E slides were also used to score the 
tumour stroma percentage (TSP) and tumour budding as 
previously reported [59-61]. Briefly, at ×5 magnification, 
an area representative of the tumour invasive margin 
was selected, and then single field of ×10 magnification 
was examined, ensuring that tumour cells were present 
at all four sides of the image and the area of stroma was 
calculated as a percentage; low grade TSP (≤50%) or high 
grade (>50%). For budding, an area representative of the 
tumour invasive margin was selected at ×5 magnification, 
and a grid of 0.385mm2 size was drawn at five highest 
budding areas. The highest bud count per field was used 
as the number of buds.
Immunohistochemistry of STAT1 and STAT3
Immunohistochemical expression of total STAT1, 
Y701 phosphorylated STAT1 (ph-STAT1) total STAT3 and 
Y705 phosphorylated STAT3 (ph-STAT3) were carried 
out using a previously constructed TMA. Sections of 
2.5 µm thickness from each TMA block were placed on 
silanized glass slides. Sections were dewaxed in xylene 
before being rehydrated using graded alcohols. Antigen 
retrieval for all STATs isoforms was performed using Tris-
EDETA buffer (pH 8) for 20 minutes before cooling for 
20 minutes. Endogenous peroxidase activity was blocked 
using 3% hydrogen peroxide for 20 minutes before 
rinsing in water. Normal horse serum at dilution 1:10 was 
applied for 30 minutes at room temperature as a blocking 
solution. TMA sections were then incubated overnight at 
4oC with the primary antibodies as following: total STAT1 
(STAT1 (42H3) Rabbit monoclonal antibody, code 9175, 
Cell Signaling Technology, USA) at a concentration of 
1:100; ph-STAT1 (Rabbit PAb to STAT1 phosphoY701, 
code ab30645, Abcam, Cambridge) at a concentration of 
1:150; total STAT3 (STAT3 Rabbit Ab, code 9132L, Cell 
Signaling Technology, USA) at a concentration of 1:200; 
Ph-STAT3 (Y705) antibody (P-STAT3 (Y705) Rabbit 
Ab, code 9131L, Cell Signaling Technology, USA) at 
a concentration of 1:200. Sections were then washed in 
TBS for ten minutes. Envision (Dako) was then added to 
the sections for 30 minutes at room temperature before 
washing in TBS for ten minutes. DAB substrate was 
added for five minutes until colour developed before 
washing in running water for ten minutes. Slides were then 
counterstained in haematoxylin for 60 seconds and blued 
with Scotts’ tap water before being dehydrated through a 
series of graded alcohols. Cover slips were applied using 
distrene, plasticizer, xylene (DPX). Negative and positive 
controls were included in the staining runs.
Slide scanning and scoring
Stained TMA sections were scanned using a 
Hamamatsu NanoZoomer (Welwyn Garden City, 
Hertfordshire, UK) at x20 magnification and visualization 
was carried out using Slidepath Digital Image Hub, version 
4.0.1 (Slidepath, Leica Biosystems, Milton Keynes, UK). 
Assessment of total STAT1, ph-STAT1, total STAT3 and 
ph-STAT3 expression within the cancer cell cytoplasm and 
nucleus was performed by a single examiner (FJG) blinded 
to clinical data at x20 magnification (total magnification 
x40) using the weighted histoscore. The weighted 
histoscore provides an assessment of the percentage and 
density of staining and is calculated as follows: 0x% not 
stained + 1x% weakly stained + 2x % moderately stained 
+ 3x % strongly stained. This gives a range of scores 
from 0 to 300. Total and ph-STATs expression within 
the cytoplasm and nucleus were calculated separately. 
To ensure reproducibility of scoring, 15% of tumours for 
each antibody was co-scored by a second investigator 
(J.E.) blinded to other data. The intraclass correlation 
coefficient (ICCC) was 0.852 and 0.831 for cytoplasmic 
and nuclear total STAT1 respectively, and 0.797 and 
0.871 for cytoplasmic and nuclear ph-STAT1 respectively. 
The ICCC was 0.795 and 0.801 for cytoplasmic and 
nuclear total STAT3 respectively, and 0.814 and 0.782 
for cytoplasmic and nuclear ph-STAT3 respectively, 
indicating good agreement.
Statistical analysis
For the purpose of statistical analysis, patients 
were split into two groups on the basis of the mean value 
of cytoplasmic and nuclear STAT1/STAT3 weighted 
histoscore, as low cytoplasmic and low nuclear STAT1/
STAT3 expression and high cytoplasmic or high nuclear 
STAT1/STAT3 expression. In order to identify the impact 
of cellular STAT1/STAT3 expression at both cytoplasmic 
and nuclear location, an expression code was developed 
(STAT1/STAT3 tumour cell expression) as follows: 
patients with both low cytoplasmic and nuclear expression 
were classified as the low tumour cell expression group, 
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patients with either cytoplasmic or nuclear expression is 
low were classified as the moderate tumour cell expression 
group, and patients with both high cytoplasmic and high 
nuclear expression were classified as the high tumour cell 
expression group. These analyses have been applied for 
total and for ph-STAT1 separately and total and ph-STAT3 
separately.
Subsequently, the relationship between 
clinicopathological characteristics, ph-STAT1 tumour 
cell expression and ph-STAT3 tumour cell expression 
were examined using the Chi-square test for linear 
trend. The relationship between total and ph-STAT1 
tumour cell expression, total and ph-STAT3 tumour cell 
expression and cancer-specific survival was examined 
using Kaplan-Meier log-rank analysis. Univariate survival 
analysis was performed using Cox proportional hazards 
regression. Variables with P-value of <0.1 were entered 
into a multivariable model using a backwards conditional 
method. A P-value <0.05 was considered statistically 
significant. All analyses were performed using SPSS 
version 22.0 (IBM SPSS).
Patients were routinely followed-up following 
surgery. Date and cause of death was cross-checked with 
the cancer registration system and the Registrar General 
(Scotland). Death records were complete until 31st of May 
2013 and that served as the censor date. Cancer-specific 
survival was measured from the date of primary surgery 
until the date of death from breast cancer.
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